發改委:“十四五”時期圍繞生物醫藥、生物農業、生物製造等領域培育一批世界級龍頭企業
格隆匯5月10日丨國家發展改革委今日印發《“十四五”生物經濟發展規劃》。規劃提出,建設生物經濟創新發展高地。服務國家重大區域戰略,引導創新資源向京津冀、長三角、粵港澳大灣區集聚發展,圍繞生物醫藥、生物農業、生物製造等領域培育一批世界級龍頭企業,促進城市間產業分工協作和要素有序流動,加快提升產業鏈供應鏈現代化水平。發揮北京、上海、江蘇、廣東、成渝雙城經濟圈等地區生物產業體系完備、科研基礎紮實、醫療資源豐富、國際化程度較高等優勢,集中力量組織實施重點產業專項提升行動,先行先試改革舉措,打造具有全球競爭力和影響力的生物經濟創新極和生物產業創新高地。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.